| SKŘIČKOVÁ, Jana, Zbyněk BORTLÍČEK, Karel HEJDUK, Miloš PEŠEK, Vítězslav KOLEK, Jaromír ROUBEC, Marcela TOMÍŠKOVÁ, Monika ŠATÁNKOVÁ, Zdenka POVOLNÁ, Helena ČOUPKOVÁ, František SALAJKA, Dimka SIXTOVÁ, Leona KOUBKOVÁ, Libor HAVEL, Michal HRNCIARIK, Milada ZEMANOVÁ a Markéta ČERNOVSKÁ. Pemetrexed in combination with cisplatin in the first-line treatment of non-squamous NSCLC: Czech experience with 233 patients. In 15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia. 2013. ISSN 1556-0864. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1136260,
author = {Skřičková, Jana and Bortlíček, Zbyněk and Hejduk, Karel and Pešek, Miloš and Kolek, Vítězslav and Roubec, Jaromír and Tomíšková, Marcela and Šatánková, Monika and Povolná, Zdenka and Čoupková, Helena and Salajka, František and Sixtová, Dimka and Koubková, Leona and Havel, Libor and Hrnciarik, Michal and Zemanová, Milada and Černovská, Markéta},
booktitle = {15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia},
keywords = {first-line treatment; NSCLC},
language = {eng},
title = {Pemetrexed in combination with cisplatin in the first-line treatment of non-squamous NSCLC: Czech experience with 233 patients},
year = {2013}
}
TY - CONF
ID - 1136260
AU - Skřičková, Jana - Bortlíček, Zbyněk - Hejduk, Karel - Pešek, Miloš - Kolek, Vítězslav - Roubec, Jaromír - Tomíšková, Marcela - Šatánková, Monika - Povolná, Zdenka - Čoupková, Helena - Salajka, František - Sixtová, Dimka - Koubková, Leona - Havel, Libor - Hrnciarik, Michal - Zemanová, Milada - Černovská, Markéta
PY - 2013
TI - Pemetrexed in combination with cisplatin in the first-line treatment of non-squamous NSCLC: Czech experience with 233 patients
KW - first-line treatment
KW - NSCLC
N2 - In a group of 233 patients with advanced non-squamous NSCLC who were treated with pemetrexed in first line and in combination with cisplatin, the therapy was well tolerated: termination of treatment due to adverse events was reported only in 3.8% of patients. Median overall was 11.6 months, median progression-free survival was 4.2 months.
ER -
SKŘIČKOVÁ, Jana, Zbyněk BORTLÍČEK, Karel HEJDUK, Miloš PEŠEK, Vítězslav KOLEK, Jaromír ROUBEC, Marcela TOMÍŠKOVÁ, Monika ŠATÁNKOVÁ, Zdenka POVOLNÁ, Helena ČOUPKOVÁ, František SALAJKA, Dimka SIXTOVÁ, Leona KOUBKOVÁ, Libor HAVEL, Michal HRNCIARIK, Milada ZEMANOVÁ a Markéta ČERNOVSKÁ. Pemetrexed in combination with cisplatin in the first-line treatment of non-squamous NSCLC: Czech experience with 233 patients. In \textit{15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia}. 2013. ISSN~1556-0864.
|
